As equity markets face sustained volatility, investors are actively seeking high-quality assets that can withstand economic downturns. Professional analysts highlight three key characteristics to focus on in a bear market: sustainable profitability, stable dividend payouts, and exposure to recession-resistant industries. The healthcare sector, with its inelastic demand, has historically demonstrated resilience during market slumps. However, investors should note that even stable dividends from quality companies do not make them immune to share price fluctuations.
Investment decisions must adhere to the principle of full diversification, avoiding over-concentration. When constructing a portfolio, a comprehensive evaluation of each stock’s cash flow, dividend sustainability, and business prospects is essential for maintaining composure amidst market volatility.
Here are three leading healthcare companies worthy of consideration in the current market environment.
As an integrated healthcare group spanning retail pharmacy, basic medical services, and health insurance, CVS Health Corporation (NYSE: CVS) exhibits unique defensive attributes during economic downturns. Its extensive network of community-based pharmacies and MinuteClinics serves as a primary channel for residents accessing essential medical services. Although recent increases in Medicare utilization and rising healthcare costs have temporarily impacted the company’s earnings growth, its dividend remains stable. The current dividend yield exceeds 3%, and its appeal continues to strengthen as the stock price has adjusted.
As a globally leading biopharmaceutical company, AbbVie (NYSE: ABBV) represents a quality asset worth holding in a bear market, thanks to its solid dividend policy and innovative drug pipeline. The company offers a forward dividend yield of approximately 3%. While maintaining a dividend growth streak spanning over six decades, it continues to generate revenue through its core product portfolios in areas like immunology and oncology. Demographic trends such as an aging population and the inelastic nature of healthcare demand provide long-term growth tailwinds for this industry behemoth.
As a “Dividend King” with over 60 consecutive years of dividend increases, Johnson & Johnson (NYSE: JNJ) remains a core holding for income-focused investors. Following a corporate restructuring that spun off its slower-growth consumer health division (known for products like Band-Aids and Tylenol) into the separate, publicly traded company Kenvue, J&J is now more focused on high-growth areas like immunology, oncology, and medical devices. Based on the current share price, Johnson & Johnson’s dividend yield sits around 3%, providing investors with a substantial income stream.
